81 candidate markets, 39 the client already served — and the top-ranked lead was wrong.
An established chemical, already selling into a handful of well-served markets. Every figure below traces back to the document it came from.
candidate markets found for one established chemical
markets the client already served, subtracted automatically before ranking
from starting to a sourced go-to-market foundation on that first engagement, with the gaps named
The lead that did not survive
The top-scoring lead was rejected. Every document behind it turned out to describe a business the client already ran, under a name our list had not matched — not white space at all, but the same business under another name. The second lead was put through the same check and survived it.
The three questions, answered
Is it real?Yes, for the chemistry.
The family is already sold commercially into that application, which proves it rather than predicts it. Not yet proven for the client's own material — and the report says so rather than glossing it.
Is it worth it?Register-verified, not brochure-claimed.
US volumes for the molecule and its family have risen sharply since 2020 while imports of the family's trade basket have fallen — import substitution, confirmed in two official sources rather than claimed in a brochure.
Can we win?The file is clean; the field is not.
Clean regulatory standing on both sides of the Atlantic, and new EU registrants have appeared in recent years — others are moving. The incumbents and the patents sit elsewhere, so the window is measured in filings per year rather than in sentiment.